Efficacy of reconstituted intravenous fentanyl to sublingual solution versus oral morphine syrup for breakthrough pain among patients with chronic gynecologic cancer pain: A randomized, double‐blind, placebo‐controlled trial
Journal of Obstetrics and Gynaecology Research · 2023
DOI: 10.1111/jog.15674 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2023. Verfasst von Thitirath Thantiprechapong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Rajavithi Hospital, Bangkok, Thailand. Hauptthemen laut MEDLINE: Analgesics, Opioid, Breakthrough Pain, Cancer Pain, Fentanyl. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: The Rajavithi Research Management Fund.
Abstract (Originalsprache)
Rapid‐acting fentanyl formulations are superior to oral morphine (OM) syrup in controlling breakthrough pain among patients with cancer, but they are expensive and unavailable in many countries.
Objective
To evaluate the efficacy of reconstituted intravenous fentanyl to sublingual solution (IFS) in relieving breakthrough pain as compared with OM.
Methods
In this randomized, double‐blind, double‐dummy, placebo‐controlled trial, patients with gynecologic cancer aged ≥18 years experiencing chronic cancer pain with breakthrough pain were enrolled. Patients were randomly allocated (1:1) to receive either 50 μg IFS or 5 mg OM. Pain intensity level was assessed at 5, 15, 30, 45, 60, and 120 min after treatment. The primary outcome was the reduction in pain intensity at 15 min in the intention‐to‐treat population ( ClinicalTrials.gov , NCT05037539).
Results
Between June 15, 2021 and December 30, 2021, 40 participants were equally and randomly assigned to receive IFS or OM. The primary outcome was significantly higher in the IFS group (4.25 vs. 1.05, p < 0.0001). The secondary outcomes also showed higher reduction in pain intensity at 5 min in the IFS group. Subsequent breakthrough pain did not differ between the two groups. However, the reduction in pain was lower in the IFS group at 45, 60, and 120 min, where pain was classified as mild. No severe adverse effects were observed in both groups. Burning sensation without noticeable lesion was found in 20% of the IFS group.
Conclusion
IFS can reduce early breakthrough pain. IFS may be considered for breakthrough pain when rapid‐acting fentanyl formulations are unavailable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Rajavithi Hospital, Bangkok, Thailand.
- College of Medicine, Rangsit University, Bangkok, Thailand.
- Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand.
ORCID-Profile: Vasin Vasikasin
Förderung
- The Rajavithi Research Management Fund
Zitieren
APA
Thantiprechapong, T., Tilagul, T., & Vasikasin, V. (2023). Efficacy of reconstituted intravenous fentanyl to sublingual solution versus oral morphine syrup for breakthrough pain among patients with chronic gynecologic cancer pain: A randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.15674
Vancouver
Thantiprechapong T, Tilagul T, Vasikasin V. Efficacy of reconstituted intravenous fentanyl to sublingual solution versus oral morphine syrup for breakthrough pain among patients with chronic gynecologic cancer pain: A randomized, double‐blind, placebo‐controlled trial. Journal of Obstetrics and Gynaecology Research. 2023. doi:10.1111/jog.15674
BibTeX
@article{Thantiprechapong2023,
author = {Thantiprechapong, Thitirath and Tilagul, Thanvarat and Vasikasin, Vasin},
title = {Efficacy of reconstituted intravenous fentanyl to sublingual solution versus oral morphine syrup for breakthrough pain among patients with chronic gynecologic cancer pain: A randomized, double‐blind, placebo‐controlled trial},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2023},
doi = {10.1111/jog.15674}
}
EUVIMED